SIRIO(SZ:300791) Huachuang Securities·2026-01-30 07:30Investment Rating - The report maintains a "Strong Buy" rating for Xianle Health, indicating an expectation to outperform the benchmark index by over 20% in the next six months [10]. Core Insights - The company has released its 2025 earnings forecast, projecting a net profit attributable to shareholders between 101 million to 151 million yuan, representing a year-on-year decline of 68.85% to 53.44% [2]. - The company has introduced a 2026 restricted stock incentive plan, granting 2.2025 million shares at a price of 12.21 yuan per share, covering 85 management and core technical personnel [2]. - The company aims to achieve revenue targets of no less than 50.90 billion yuan, 53.83 billion yuan, and 58.32 billion yuan for the years 2026 to 2028, respectively [2]. - The company has also revised its 2023/2025 equity incentive plans, adjusting revenue targets downwards for 2026 [2]. Financial Performance - Total revenue is projected to grow from 4.211 billion yuan in 2024 to 5.536 billion yuan in 2027, with a compound annual growth rate (CAGR) of approximately 8.8% [10]. - The net profit is expected to recover significantly from 121 million yuan in 2025 to 458 million yuan in 2027, reflecting a growth rate of 19.5% [10]. - The company’s asset-liability ratio stands at 53.22%, indicating a moderate level of financial leverage [5]. Market Position - The global nutrition and health solutions market is expected to grow from 29.4 billion USD in 2024 to 42.4 billion USD by 2029, with a CAGR of 7.6% [11]. - Xianle Health ranks third globally in the nutrition and health food solutions market, holding a 2.0% market share, with notable strengths in gummy and soft capsule segments [9][11]. - The company is well-positioned to capture market share due to its strong R&D capabilities and a robust supply chain [9]. Incentive Plans - The 2026 restricted stock incentive plan aims to align management and technical personnel's performance with company growth, focusing on both revenue and profit targets [2]. - The employee stock ownership plan covers up to 12 core management members, with profit targets set at no less than 3.8 billion yuan for 2026 and 4.5 billion yuan for 2027 [2][21].